Display options
Cite
Ebina K, Hirano T, Maeda Y, et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep. 2022;12(1):134doi: 10.1038/s41598-021-04075-0.
Ebina, K., Hirano, T., Maeda, Y., Yamamoto, W., Hashimoto, M., Murata, K., Onishi, A., Jinno, S., Hara, R., Son, Y., Amuro, H., Takeuchi, T., Yoshikawa, A., Katayama, M., Yamamoto, K., Okita, Y., Hirao, M., Etani, Y., Kumanogoh, A., Okada, S., & Nakata, K. (2022). Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Scientific reports, 12(1), 134. https://doi.org/10.1038/s41598-021-04075-0
Ebina, Kosuke, et al. "Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study." Scientific reports vol. 12,1 (2022): 134. doi: https://doi.org/10.1038/s41598-021-04075-0
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Onishi A, Jinno S, Hara R, Son Y, Amuro H, Takeuchi T, Yoshikawa A, Katayama M, Yamamoto K, Okita Y, Hirao M, Etani Y, Kumanogoh A, Okada S, Nakata K. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep. 2022 Jan 07;12(1):134. doi: 10.1038/s41598-021-04075-0. PMID: 34997059; PMCID: PMC8742057.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2022 Jan 07;12(1):134. doi: 10.1038/s41598-021-04075-0.

Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.

Scientific reports

Kosuke Ebina, Toru Hirano, Yuichi Maeda, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Akira Onishi, Sadao Jinno, Ryota Hara, Yonsu Son, Hideki Amuro, Tohru Takeuchi, Ayaka Yoshikawa, Masaki Katayama, Keiichi Yamamoto, Yasutaka Okita, Makoto Hirao, Yuki Etani, Atsushi Kumanogoh, Seiji Okada, Ken Nakata

Affiliations

  1. Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. [email protected].
  2. Department of Rheumatology, Nishinomiya Municipal Hospital, Hyogo, Japan.
  3. Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
  4. Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan.
  5. Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.
  6. Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  7. Department of Clinical Immunology, Osaka City University Graduate School of Medicine, Osaka, Japan.
  8. Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Hyogo, Japan.
  9. Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan.
  10. First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  11. Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
  12. Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan.
  13. Information Technology Center, Wakayama Medical University, Wakayama, Japan.
  14. Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
  15. Department of Health and Sport Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.

PMID: 34997059 PMCID: PMC8742057 DOI: 10.1038/s41598-021-04075-0

Abstract

This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with either BAR (n = 166) or TOF (n = 185); bDMARDs- or JAKi-switched cases (76.6%). The reasons for drug discontinuation were classified into four major categories. The drug retention was evaluated at 24 months using the Kaplan-Meier method and multivariate Cox proportional hazards modelling adjusted by confounders. Discontinuation rates for the corresponding reasons were as follows; ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%) and remission (0.0%). Prior history of anti-interleukin-6 receptor antibody (aIL-6R) ineffectiveness significantly increased the risk of treatment discontinuation due to ineffectiveness (p = 0.020). Aging (≥ 75 years) (p = 0.028), usage of PSL ≥ 5 mg/day (p = 0.017) and female sex (p = 0.041) significantly increased the risk of treatment discontinuation due to toxic adverse events. Factors not associated with treatment discontinuation were: number of prior bDMARDs or JAKi, concomitant MTX usage, difference of JAKi, and prior use of TNF inhibitor, CTLA4-Ig or other JAKi.

© 2022. The Author(s).

References

  1. RMD Open. 2017 Jan 3;3(1):e000363 - PubMed
  2. PLoS One. 2017 Jun 8;12(6):e0179179 - PubMed
  3. Rheumatology (Oxford). 2015 Sep;54(9):1664-72 - PubMed
  4. JAMA. 2018 Oct 2;320(13):1360-1372 - PubMed
  5. Rheumatology (Oxford). 2016 May;55(5):874-82 - PubMed
  6. Arthritis Care Res (Hoboken). 2019 Sep;71(9):1249-1254 - PubMed
  7. Pharmacol Rep. 2006 Jul-Aug;58(4):473-92 - PubMed
  8. Rheumatology (Oxford). 2015 Dec;54(12):2156-65 - PubMed
  9. Arthritis Rheum. 2009 May 15;61(5):560-8 - PubMed
  10. Rheumatology (Oxford). 2011 Jan;50(1):117-23 - PubMed
  11. Ann Rheum Dis. 2012 Jul;71(7):1134-42 - PubMed
  12. Arthritis Res Ther. 2018 Aug 3;20(1):165 - PubMed
  13. J Rheumatol. 2014 Jan;41(1):15-23 - PubMed
  14. Immunity. 2018 Jun 19;48(6):1220-1232.e5 - PubMed
  15. Arthritis Rheumatol. 2019 Sep;71(9):1450-1459 - PubMed
  16. Clin Rheumatol. 2021 Jul;40(7):2673-2680 - PubMed
  17. Arthritis Res Ther. 2019 Apr 11;21(1):91 - PubMed
  18. RMD Open. 2017 Oct 10;3(2):e000546 - PubMed
  19. Ann Rheum Dis. 2015 Feb;74(2):354-60 - PubMed
  20. Mod Rheumatol. 2020 Jan;30(1):36-43 - PubMed
  21. Clin Exp Rheumatol. 2021 Jul-Aug;39(4):868-873 - PubMed
  22. Clin Rheumatol. 2020 Sep;39(9):2563-2572 - PubMed
  23. PLoS One. 2018 Mar 15;13(3):e0194130 - PubMed
  24. Mod Rheumatol. 2007;17(6):451-8 - PubMed
  25. Arthritis Res Ther. 2021 Apr 15;23(1):116 - PubMed
  26. Arthritis Rheumatol. 2016 Nov;68(11):2612-2617 - PubMed
  27. Arthritis Rheumatol. 2014 Nov;66(11):2924-37 - PubMed
  28. J Rheumatol. 2018 Feb;45(2):177-187 - PubMed
  29. Z Rheumatol. 2019 Aug;78(6):559-567 - PubMed
  30. Mod Rheumatol. 2009;19(4):351-7 - PubMed
  31. Nat Rev Rheumatol. 2017 Apr;13(4):234-243 - PubMed
  32. Bone Marrow Transplant. 2013 Mar;48(3):452-8 - PubMed
  33. Sci Rep. 2020 Dec 14;10(1):21907 - PubMed
  34. Clin Rev Allergy Immunol. 2019 Jun;56(3):333-345 - PubMed
  35. Arthritis Rheum. 1988 Mar;31(3):315-24 - PubMed
  36. Rheumatol Int. 2021 Jul;41(7):1233-1241 - PubMed
  37. Arthritis Rheumatol. 2017 Mar;69(3):506-517 - PubMed
  38. Rheumatology (Oxford). 2014 Sep;53(9):1664-8 - PubMed
  39. Arthritis Res Ther. 2020 Jun 15;22(1):142 - PubMed
  40. Clin Exp Rheumatol. 2021 May-Jun;39(3):525-531 - PubMed
  41. Ann Rheum Dis. 2020 Jun;79(6):685-699 - PubMed
  42. Ann Rheum Dis. 2010 Sep;69(9):1580-8 - PubMed
  43. Rheumatology (Oxford). 2021 Sep 1;60(9):4048-4054 - PubMed
  44. PLoS One. 2019 May 8;14(5):e0216624 - PubMed
  45. Nihon Rinsho. 2016 Jun;74(6):939-43 - PubMed
  46. Arthritis Care Res (Hoboken). 2016 Apr;68(4):432-9 - PubMed

Publication Types